Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy
Methods of enhancing immune response to an immunogen in a subject are disclosed. Also disclosed are methods of reducing the sensitivity to an allergen in a subject. The methods comprise the administration of an immunomodulatory compound in specific dosing regimens that result in enhanced immune response or reduced sensitivity.
1. A method of eliciting an enhanced immune response from an immunogen in a subject comprising administering to the subject an immunomodulatory compound prior to initial introduction of the immunogen as a vaccine to the subject, wherein the immunomodulatory compound is a compound of formula I, or a pharmaceutically acceptable salt or stereoisomer thereof:
wherein:
one of X and Y is C═O, the other of X and Y is C═O or CH 2 ;
R 2 is hydrogen or lower alkyl.
2. The method of claim 1 , wherein the immunomodulatory compound is administered from about 10 days to about 12 hours prior to the introduction of an immunogen.
3. The method of claim 2 , wherein the immunomodulatory compound is administered from about 7 days to about 12 hours prior to the introduction of an immunogen.
4. The method of claim 3 , wherein the immunomodulatory compound is administered from about 5 days to about 1 day prior to the introduction of an immunogen.
5. The method of claim 4 , wherein the immunomodulatory compound is administered from about 3 days to about 1 day prior to the introduction of an immunogen.
6. The method of claim 1 , which further comprises a second administration of an immunomodulatory compound after the introduction of an immunogen.
7. The method of claim 6 , wherein the immunomodulatory compound is administered from about 12 hours to about 10 days after the introduction of an immunogen.
8. The method of claim 7 , wherein the immunomodulatory compound is administered from about 12 hours to about 7 days after the introduction of an immunogen.
9. The method of claim 8 , wherein the immunomodulatory compound is administered from about 1 day to about 5 days after the introduction of an immunogen.
10. The method of claim 9 , wherein the immunomodulatory compound is administered from about 1 day to about 3 days after the introduction of an immunogen.
11. The method of claim 1 , wherein the immunogen comprises a tumor antigen.
12. The method of claim 1 , wherein the immunomodulatory compound is 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione.
13. The method of claim 12 , wherein the immunomodulatory compound is enantiomerically pure.
14. The method of claim 1 , wherein the immunomodulatory compound is 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione.
15. The method of claim 14 , wherein the immunomodulatory compound is enantiomerically pure.